SCHEMBL5006969

SCHEMBL5006969

Nc1ccc(Cl)cc1Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.62
ALOX15 P16050 2/20 0.62
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
HPGD P15428 1/20 0.62
HIF1A Q16665 1/20 0.62
HSD17B10 Q99714 1/20 0.62
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
BCL2 P10415 1/20 0.44
BCL2L1 Q07817 1/20 0.44
HTR2A P28223 1/20 0.41
CALM1 P0DP23 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MPO P05164 1/20 0.41
TPO P07202 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11778511 0.87 PNMT (0.52) CYP3A4ALOX15KMT2AMEN1HPGD
SCHEMBL9656059 0.85 CYP3A4 (0.58) CYP3A4ALOX15KMT2AMEN1HPGD
SCHEMBL9658439 0.81 CYP3A4 (0.42) CYP3A4ALOX15KMT2AMEN1HPGD
SCHEMBL6839208 0.80 HTR2A (0.48) CYP3A4TSHRALDH1A1TDP1BCL2
SCHEMBL28691380 0.80 CYP3A4 (0.56) CYP3A4ALOX15KMT2AMEN1HPGD
SCHEMBL3618843 0.80 MEN1 (0.67) CYP3A4ALOX15KMT2AMEN1HPGD
SCHEMBL3251975 0.79 CYP3A4 (0.47) CYP3A4ALOX15KMT2AMEN1HPGD
SCHEMBL22898008 0.79 TSHR (0.50) CYP3A4ALOX15KMT2AMEN1HPGD
SCHEMBL22232424 0.78 CYP3A4 (0.50) CYP3A4ALOX15KMT2AMEN1HPGD
SCHEMBL11030384 0.77 CYP3A4 (0.62) CYP3A4ALOX15KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-58225017-A None JP disclosed
CN-115433346-B Palladium catalyst based on phenanthrenequinone alpha-diamine, and preparation method and application thereof 武汉工程大学 2024-03-26 CN disclosed
CN-115433346-A Phenanthrenequinone alpha-diamine-based palladium catalyst and preparation method and application thereof 武汉工程大学 2022-12-06 CN disclosed
US-7414063-B2 Inhibitors of Akt (protein kinase B) ELI LILLY AND COMPANY (US) 2008-08-19 US disclosed
US-20070043040-A1 Inhibitors of akt (protein kinase b) ELI LILLY AND COMPANY 2007-02-22 US disclosed
CN-1768040-A Isoquinoline-5-sulfonic acid amides as inhibitors of AKT (protein kinase B) LILLY CO ELI (US) 2006-05-03 CN disclosed
EP-1611105-A1 ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) ELI LILLY AND COMPANY (US) 2006-01-04 EP disclosed
WO-2004094386-A1 ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) ELI LILLY AND COMPANY (US) 2004-11-04 WO disclosed
EP-0301549-B1 1-[2-(Phenylmethyl)phenyl]-piperazine compounds, a process for preparing them and pharmaceutical compostions containing them FERRER INTERNACIONAL, S.A. (ES) 1992-10-28 EP disclosed
US-5091415-A Antiulcer, antisecretory agents PIERRE FABRE MEDICAMENT (FR) 1992-02-25 US disclosed
US-5025015-A Antisecretory and antiulcer agents PIERRE FABRE MEDICAMENT (FR) 1991-06-18 US disclosed
US-4859675-A 1-[2-(phenylmethyl) phenyl]piperazines as antidepressants FERRER INTERNACIONAL S.A. (ES) 1989-08-22 US disclosed
EP-0301549-A1 1-[2-(Phenylmethyl)phenyl]-piperazine compounds, a process for preparing them and pharmaceutical compostions containing them FERRER INTERNACIONAL, S.A. (ES) 1989-02-01 EP disclosed
EP-0048998-B1 ISONICOTINANILIDE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND PLANT GROWTH REGULATOR CONTAINING THE SAME Chugai Seiyaku Kabushiki Kaisha (JP) 1985-01-09 EP disclosed
JP-S58225017-A AGENT FOR ELIMINATING CANCER CHUGAI PHARMACEUT CO LTD 1983-12-27 JP disclosed
US-4377407-A Isonicotinanilide derivatives, plant growth regulating compositions and use CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1983-03-22 US disclosed
US-3992400-A 1-(α-Phenyl-o-tolyl)imidazoles THE UPJOHN COMPANY (US) 1976-11-16 US disclosed
US-3941802-A 2-(Imidazol-1-yl)benzophenones THE UPJOHN COMPANY (US) 1976-03-02 US disclosed
US-3941803-A 2-(Imidazol-1-yl)benzophenones THE UPJOHN COMPANY (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043040-A1 Inhibitors of akt (protein kinase b) AKT1, AKT2, BRAF CYP3A4 3139/4885ALOX15 4158/4885KMT2A 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.